Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Held during Abu Dhabi Global Health Week, the roundtable united global health leaders to shape a Declaration on AI governance ...

Without a carve-out for tariff exceptions for pharmaceuticals, prices will skyrocket for US patients, experts warn.

A growing number of pharmaceutical companies are sharing plans to ramp up domestic manufacturing capacity amid recent tariffs imposed by the Trump administration. Here are five things to know: ...

Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal ...

Roche will invest $50 billion in U.S. manufacturing, including a new plant in Indiana. The Trump administration is ...

Numerous companies have unveiled investments in U.S. manufacturing in recent weeks, including TSMC, Eli Lilly, Hyundai Motor ...

The announcement comes as drugmakers unveil investments to deal with tariffs from the Trump administration, which is seeking to boost domestic manufacturing ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug Wegovy two years after reporting initial Phase 3 results.

The MoU was signed by H.E. Ibrahim Al Jallaf, Executive Director of Digital Health at DoH and Naim Yazbeck, Country General ...

CEO Dave Ricks said Friday that the company will make its planned GLP-1 weight-loss pill in the U.S. amid President Donald ...

Eli Lilly & Co. plans to manufacture its new weight-loss pill in the US for patients around ... But Lilly is already ...